The Food Allergy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Food Allergy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Food Allergy Market.
Some of the key takeaways from the Food Allergy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Food Allergy treatment therapies with a considerable amount of success over the years.
- Food Allergy companies working in the treatment market are Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, DBV Technologies, and others, are developing therapies for the Food Allergy treatment
- Emerging Food Allergy therapies in the different phases of clinical trials are- INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, DBV 135, and others are expected to have a significant impact on the Food Allergy market in the coming years.
- In November 2022, From the 2022 ACAAI meeting in Louisville, KY, Medpage reported on omalizumab (Xolair) which isproving to be an effective therapy for patients with multiple food allergies according to an ongoing phase 3 study namedOUtMATCH.
- In April 2022, According to a statement from Intrommune Therapeutics, the Maximum Tolerable Dose (MTD) has been adjusted for the ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. Cohort 1 successfully increased the dosage to Dose 4 as previously announced, with no serious side effects. In order to find both an MTD and a safe beginning dose of INT301, patients with peanut allergies in Cohort 2 were started at Dose 2 and are being up-titrated through 11 escalating doses. Participants in Cohort 4 are anticipated to begin at Dose 4, while patients in Cohort 3 are beginning at Dose 3. Participants in Cohort 2 have successfully been up-titrated through 11 dosages. Enrollment for Cohort 3 is currently open. There haven’t been any noteworthy adverse incidents to date.
- In March 2022, Aravax reported that the U.S. Food and Drug Administration (FDA) had approved its application for an Investigational New Drug (IND). The next-generation allergen-specific immunotherapy PVX108 accurately targets the T cells responsible for peanut allergy by utilising peptides that stand in for important peanut protein components.
- In January 2022, The Phase 1/2 study using ADP101 for the treatment of food allergies (FA), Harmony, by Alladapt Immunotherapeutics Inc., has completed patient enrolment.The Company’s primary programme, DP101, is an oral immunotherapy (OIT) that may be best in class. It is intended to desensitise patients who are simultaneously allergic to one or more foods in order to reduce the risk of serious, life-threatening allergic reactions.
- In March 2021, The UK’s research and innovation organisation, Innovate UK, announced that Cambridge Allergy Ltd has received funding totaling £1.1M through the program’s Biomedical Catalyst Award. The company intended to advance CA002, an immunotherapy for peanut allergies, using the £1.1M in non-dilutive capital.
Food Allergy Overview
A food allergy develops when the immune system of the body perceives a particular meal as hazardous and responds by producing symptoms. An allergic reaction has occurred. Allergens include foods that trigger allergic reactions.
Get a Free Sample PDF Report to know more about Food Allergy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/food-allergy-pipeline-insight
Emerging Food Allergy Drugs Under Different Phases of Clinical Development Include:
- INT301: Intrommune Therapeutics
- AIMab7195: Xencor
- VE416: Vedanta Biosciences
- ADP101: Alladapt Immunotherapeutics
- PVX-108: Aravax
- Dupilumab: Regeneron
- DBV 135: DBV Technologies
- Ligelizumab: Novartis AG
- CA002: Camallergy
- Omalizumab: Genentech
- GI 301: GI Innovation
- DBV 135: DBV Technologies
Food Allergy Route of Administration
Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Food Allergy Molecule Type
Food Allergy Products have been categorized under various Molecule types, such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Food Allergy Pipeline Therapeutics Assessment
- Food Allergy Assessment by Product Type
- Food Allergy By Stage and Product Type
- Food Allergy Assessment by Route of Administration
- Food Allergy By Stage and Route of Administration
- Food Allergy Assessment by Molecule Type
- Food Allergy by Stage and Molecule Type
DelveInsight’s Food Allergy Report covers around 35+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Food Allergy product details are provided in the report. Download the Food Allergy pipeline report to learn more about the emerging Food Allergy therapies
Some of the key companies in the Food Allergy Therapeutics Market include:
Key companies developing therapies for Food Allergy are – Merck & Co, AstraZeneca, Mabylon, GI Innovation, Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta Therapeutics, IgGenix, Rho Federal Systems Division, Inc, and many others.
Food Allergy Pipeline Analysis:
The Food Allergy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Food Allergy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Food Allergy Treatment.
- Food Allergy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Food Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Food Allergy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Food Allergy drugs and therapies
Food Allergy Pipeline Market Drivers
- Increasing prevalence of food allergies, growth in commercial and scientific activities for research and development are some of the important factors that are fueling the Food Allergy Market.
Food Allergy Pipeline Market Barriers
- However, lack of Public awareness, accurate diagnosis of food allergies is critical and other factors are creating obstacles in the Food Allergy Market growth.
Scope of Food Allergy Pipeline Drug Insight
- Coverage: Global
- Key Food Allergy Companies: Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, DBV Technologies, and others
- Key Food Allergy Therapies: INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, DBV 135, and others
- Food Allergy Therapeutic Assessment: Food Allergy current marketed and Food Allergy emerging therapies
- Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers
Request for Sample PDF Report for Food Allergy Pipeline Assessment and clinical trials
Table of Contents
1. Food Allergy Report Introduction
2. Food Allergy Executive Summary
3. Food Allergy Overview
4. Food Allergy- Analytical Perspective In-depth Commercial Assessment
5. Food Allergy Pipeline Therapeutics
6. Food Allergy Late Stage Products (Phase II/III)
7. Food Allergy Mid Stage Products (Phase II)
8. Food Allergy Early Stage Products (Phase I)
9. Food Allergy Preclinical Stage Products
10. Food Allergy Therapeutics Assessment
11. Food Allergy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Food Allergy Key Companies
14. Food Allergy Key Products
15. Food Allergy Unmet Needs
16 . Food Allergy Market Drivers and Barriers
17. Food Allergy Future Perspectives and Conclusion
18. Food Allergy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services